联合健康(UNH.US)盘初一度跌超7.6%，最低触及260.55美元，创逾两个月新低。消息面上，联合健康 Q2收入为1116亿美元，略高于市场预期的1115.9美元；调整后每股收益4.08美元，低于市场预期的4.22 美元。由于各业务线的医疗成本趋势高于预期，医疗赔付率(MLR)升至89.4%，高于市场预期的89.3%。 公司更新2025年业绩展望，预计营收为4455亿至4480亿美元，调整后每股收益为16美元，远低于此前预 期的26至26.5美元。(格隆汇) （原标题：美股异动｜联合健康一度跌超7.6%创逾两个月新低 下调全年调整后每股收益指引） ...

联合健康(UNH.N)跌超5%，公司2025财年业绩指引低于市场预期。 ...

联合健康股价下跌7.5%至5月份以来的最低水平，公司2025财年业绩指引低于预期，预计将于2026年恢 复盈利增长。 ...

来源：视频滚动新闻 联合健康第二季度调整后每股收益为4.08美元，去年同期为6.80美元，市场预期为4.59美元。预计全年 调整后每股收益至少为16美元，市场预期为20.40美元。预计将在2026年恢复盈利增长。联合健康美股 盘前大幅波动，现涨0.67%。 ...

本文源自：金融界AI电报 联合健康预计本财年调整后每股收益至少为16美元，低于市场预期的20.40美元。联合健康第二季度营 收1116.2亿美元，预估为1115.8亿美元。联合健康第二季度每股收益为3.74美元，去年同期为4.54美元。 ...

来源：格隆汇APP 格隆汇7月29日｜联合健康2025年Q2营收1116亿美元，去年同期988.6亿美元，市场预期1115.22亿美 元；每股收益为3.74美元，去年同期为4.54美元。预计2025年全年收入为4455亿至4480亿美元；预计本 财年调整后每股收益至少为16美元，低于市场预期的20.40美元。预计将于2026年恢复盈利增长。 ...

联合健康(UNH.N)2025年Q2营收1116亿美元，去年同期988.6亿美元，市场预期1115.22亿美元。 （文章来源：金十数据） ...

联合健康(UNH.N)：预计将于2026年恢复盈利增长。 ...

Core Viewpoint - The reduction of funding for healthcare programs by the U.S. government is negatively impacting health insurance companies, with warnings of further deterioration in their outlook [1] Group 1: Industry Challenges - The healthcare industry is facing challenges due to congressional funding cuts and tighter insurance rules, leading to a situation where companies feel there is "nowhere to hide" [1] - Molina Healthcare's former CEO, J. Mario Molina, indicated that the entire industry is beginning to experience problems as changes in government healthcare programs disrupt revenue maximization strategies [1] Group 2: Company Impact - Companies such as Elevance, UnitedHealth, Centene, and Molina have expressed concerns about the worsening outlook due to these funding cuts [1]

Core Viewpoint - Humana Inc. is currently consolidating but may soon reverse and rally due to being oversold and approaching a support level, indicating bullish dynamics [1]. Group 1: Stock Dynamics - A stock typically remains within its usual trading range, and when it is pushed below this range by aggressive sellers, it is considered oversold [2]. - The concept of reversion to the mean suggests that oversold stocks often attract buyers who expect a price increase, potentially leading to a self-fulfilling prophecy [2]. Group 2: Indicators and Support Levels - The stochastic indicator is commonly used to determine if a stock is oversold, with lower red and blue lines indicating such conditions, which is currently the case for Humana [4]. - Humana is nearing a previously established support level, which could be bullish as remorseful sellers may place buy orders if the stock returns to this price [5]. - A significant number of buy orders at the support level could reinforce this support, creating a favorable environment for a price increase [6].